Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (564)	4/26/2000 11:05:00 PM
From: Hawkmoon	Respond to of 666

I see... So now you're the thread censor, are you? Care to share who granted you that appointment? Btw, I don't currently hold the stock, so I'm certainly not "hyping". I'm just watching and collecting info. But if you wish to engage in a public P*ssing contest, I'm always game.

To: celeryroot.com who wrote (564)	4/29/2000 11:44:00 AM
From: Bharat H. Barai	Respond to of 666

Why talk about rumors and ignore the hard data? Bexxar has gone thru extensive clinical trials and data are already published, showing extemely good results in Low Grade Lymphomas. Rituxan has shown results in intermediate grade and high grade Lymphomas too. Initially the drug will be approved for Low grade, refractory Lymphomas but as with all other drugs, it will be used as first line agent, with/without chemotherapy. The delay in refiling is bothersome, but clinical data are excellent. B.H. Barai MD Hematologist-Oncologist